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5ABSTRACT
Sargeran Katayoun. Oral Cancer in Tehran, Iran: An approach for understanding disease
burden. Department of Oral Public Health, Institute of Dentistry, University of Helsinki,
Finland, 2008. 75 pp. ISBN 978-952-10-4677-3
The present study investigated the burden of oral cancer in Tehran, Iran in terms of patient
and tumour characteristics, survival rate, and delay in diagnosis, with the main focus on
oral cavity cancers.
For exploring the characteristics of malignant oral tumours, data were obtained from
records of 1042 patients diagnosed with invasive oral cancers during 1993-2003 in 30
major hospitals in Tehran. Data were analysed in three groups: tumours of the lips, oral
cavity, and major salivary glands. For survival analysis, 470 primary oral cavity and 82 lip
cancer patients diagnosed during 1996-2003 were followed from the date of diagnosis to
late 2005.
To assess the time elapsed between patients’ first awareness of symptoms and the final
diagnosis (diagnostic delay) 100 consecutive patients with primary squamous cell
carcinoma  (SCC)  of  the  oral  cavity  who  were  referred  to  three  university  hospitals  in
Tehran during September 2004 to September 2006 were studied. Data were obtained by
means of structured questionnaire-interviews and by reviewing the medical record of each
patient. Diagnostic delay was analysed in two phases: 1) time from onset of symptoms to
the patient’s first professional visit (patient delay) and 2) time from the first professional
visit to the final diagnosis (professional delay).
At  the  time of  diagnosis,  most  oral  cavity  cancer  patients  were  at  advanced  stages.  The
overall five-year survival rates of patients with oral cavity and lip cancer were 30% and
62%, lower than rates reported from western countries. Oral cancer patients’ survival was
negatively associated with tumour stage at diagnosis. Another determinant of patients’
survival  was  treatment  modality.  Patients  treated  with  radiotherapy  as  the  sole  mode  of
treatment had lower survival rates than those treated with radiotherapy and surgery. The
findings of this study revealed that the mean diagnostic delay was high (7.2 months, SD
67.5), in particular, higher than that reported from developed countries. In general, “patient
delay”  constitutes  a  substantial  part  of  the  total  time  elapsed  between  the  onset  of
symptoms and diagnosis.
Based on the findings of this study, developing preventive programmes that focus on
raising public awareness about the signs and symptoms of oral cancer is essential in
promoting earlier diagnosis. In addition, health care professionals, especially dentists and
oral hygienists, should be empowered to improve early diagnosis and gain better treatment
outcomes for oral cancer patients in Tehran, Iran.
Author's address:
Katayoun Sargeran, Department of Oral Public Health, Institute of Dentistry, University of
Helsinki, P.O.Box 41, FI-00014 Helsinki, Finland
E-mail: katayoun.sargeran@helsinki.fi
7LIST OF ORIGINAL PUBLICATIONS
The thesis is based on the following original articles referred to in the text by their Roman
numerals.
I. Sargeran K, Murtomaa H, Safavi SM, Vehkalahti M, Teronen O.
         Malignant oral tumours in Iran: ten-year analysis on patient and tumour
         characteristics of 1042 patients in Tehran.
         Journal of Craniofacial Surgery 2006; 17: 1230-3.
II. Sargeran K, Murtomaa H, Safavi SM, Vehkalahti M, Teronen O.
         Survival after diagnosis of cancer of the oral cavity.
British Journal of Oral and Maxillofacial Surgery 2008; 46: 187-91.
III. Sargeran K, Murtomaa H, Safavi SM, Vehkalahti M, Teronen O.
         Survival after lip cancer diagnosis.
         Journal of Craniofacial Surgery (Accepted for publication)
IV. Sargeran K, Murtomaa H, Safavi SM, Teronen O.
         Delayed diagnosis of oral cancers in Iran: challenge for prevention.
         Oral Health and Preventive Dentistry (Accepted for publication)
8ABBREVIATIONS
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CI                 Confidence interval
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HPV             Human papilloma virus
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OC               Oral cavity
OR               Odds ratio
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QOL            Quality of life
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1. INTRODUCTION
Cancer  is  one  of  the  leading  causes  of  death  worldwide.  Oral  cancer,  the  most  common
cancer of the head and neck region (Stewart and Kleihues 2003), ranks eighth among the
most prevalent cancers in the world (Petersen 2003a; Petersen et al. 2005). The incidence
rate for oral cancers ranges from 0.1-31.5 per 100,000 of population per year (Moore et al.
2000; Parkin et al. 2002) with the highest rate reported from Melanesia (31.5 per 100,000
in men) and South Asia (12.7 per 100,000) (Parkin et al. 2005). Differences in incidence
across countries are particularly explicable with reference to distinct risk profiles and
etiological factors related to cultural and living conditions, lifestyles, and the
implementation of preventive oral health programmes (Stewart and Kleihues 2003;
Petersen et al. 2005; Parkin et al. 2005). The prevalence of oral cancers is higher among
men, and the peak in occurrence is around the age of 60 (Silverman 2001; Gillison 2007).
In recent decades, increases in the incidence rates have been reported from different parts
of the world such as UK (Moore et al. 2000; Conway et al. 2006), Romania (Lung et al.
2007), Pakistan (Bhurgri 2005), Taiwan (Ho et al. 2002), and Brazil (Wünsch-Filho 2002).
Despite advances in technology and treatment the survival rate has not been improved in
the last decades (Scully and Felix 2006). Oral cancer affects not only the quantity but also
the quality of life (QOL) tremendously. Both oral cancer itself and its related treatments
cause deformities in head and neck structures and several functional problems, due to the
role of the oral cavity (OC) in the vital functions of speaking, eating, chewing, and
swallowing (Rogers et al. 2007).
Oral cancer is associated with easily identifiable and detectable signs (Silverman 2001),
which should facilitate its early diagnosis. Reducing delay in diagnosis and treatment
improves the prognosis of oral cancers (Onizawa et al. 2003; Tromp et al. 2005b). Early
diagnosis of oral cancer, with increasing rapidity of referral, and improving affected
individuals’ access to multidisciplinary specialist care are priority topics in all health
programmes encouraged by the World Health Organization (WHO) (Hobdell et al. 2003;
Petersen 2005).
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The  major  risk  factors  for  oral  cancers  are  tobacco  and  alcohol  use.  Oral  health
professionals are in a position that can highly influence and actively contribute to tobacco-
cessation programmes (Petersen 2003b; Scully and Warnakulasuriya 2005). Dentists and
other dental team members are the key personnel in reducing the incidence of oral cancer
by identifying patients with high-risk behaviours and educating them about the
consequences of their behaviour, and by early detection of potentially malignant and
malignant lesions (Bsoul et al. 2005; Petti and Scully 2005; Scully et al. 2005).
The Islamic Republic of Iran covers an area of 1.6 million km2. Its population is about 70
million, with an annual growth rate of 1.5%. The country is divided into 30 provinces and
842 districts, with approximately 67% of the population living in urban areas (Iran
Statistical Year Book 2002). About half the whole population is under the age of 20 (Iran
Statistical Year Book 2002), making Iran one of the youngest countries in the world
(Pakshir 2004). A recent report indicates that cancer is the second most common cause of
non-accidental death in Iran, after cardiovascular diseases (Sadjadi et al. 2007). According
to  the  report  of  the  Iran  Ministry  of  Health  and  Medical  Education  in  2003  (IMOHME
2003), oropharyngeal cancers account for 3% of all cancers in Iran.
Integrating oral cancer information into national health surveillance systems and disease
prevention programmes, such as programmes for the prevention of cancer and
cardiovascular diseases with a focus on common risk factors, is emphasized by WHO as
an objective for oral health 2020 (Hobdell et al. 2003). Implementation of any preventive
programmes at the population level needs comprehensive assessment of the disease
burden  for  the  best  allocation  of  resources,  particularly  in  developing  countries.  The
present study aimed, for the first time, to develop an approach to understand the burden of
oral cancer in Tehran, Iran, by investigating patient and tumour characteristics, survival
rate, and delay in diagnosis, with the main focus on oral cavity cancers.
13
2. REVIEW OF THE LITERATURE
2.1. Definitions, signs, and symptoms
Oral cancers are malignancies arising in the lip, tongue, floor of the mouth (FOM),
gingiva, soft and hard palate, buccal/ vestibular mucosa, oropharynx, and salivary glands,
International Classification of diseases (ICD) coding system, ICD-10 C00-C10 (WHO
2003). About 95% of all OC and lip cancers occur in people over age 40, and average age
at the time of diagnosis is around 60 (Silverman 2003). Oral cancers usually are
malignancies whose signs and symptoms can be recognized early. More than 90% of these
cancers are carcinomas occurring in the stratified squamous epithelium lining these
anatomical areas (Silverman 2001). Of the most common sites of involvement are the
tongue, and lip. Oral cancer patients are always at risk for additional primary (second
primary) neoplasms which may arise mainly in the aerodigestive tract (Braakhuis et al.
2002; Levi et al. 2006; Scully and Felix 2006).
Squamous cell carcinoma (SSC) typically presents as a persistent mass, nodule, or
indurate ulcer. Colour changes in the squamous epithelium are common and are of red or
red and white hues. Involvement of adjacent tissues is possible and represents local
invasion of the tumour (Bsoul et al. 2005). For any single lesion with these features lasting
more than three weeks SCC should be taken into consideration and it is an indication for
urgent referral to a specialist (Scully and Felix 2006). Enlargement of a cervical lymph
node may be detectable by palpation. Symptoms of oral cancer include swelling, pain,
bleeding, and difficulty in opening the mouth, chewing, swallowing, and speech (Stewart
and Kleihues 2003). Paresthesia and anaesthesia in the absence of a history of trauma are
indicative of a malignancy. Symptoms are uncommon in earlier stages of the disease but
become frequent with advanced local invasion (Bsoul et al. 2005). In more advanced
stages, a large ulcero-prolifrative mass, with areas of necrosis and extension to
neighbouring structures such as bone, muscles, and skin may be evident (Stewart and
Kleihues 2003). Metastasis occurs through the regional lymphatic pathways and distant
metastases mostly spread to the lungs (Bsoul et al. 2005).
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Some potentially malignant lesions are clinically identifiable. Of the most important ones
are erythroplakia, leukoplakia, and lichen planus. These are characterized by increased
risk for malignant development. The overall malignant transformation rate depends on
degree of dysplasia and length of follow-up (Silverman et al. 1996). Because these lesions
are  generally  without  pain  and  discomfort,  it  is  essential  that  people  who  have  them  be
identified and kept under careful continuous clinical supervision (Scully 1995).
2.2. Epidemiology
2.2.1. Incidence
Of all diagnosed cancers, oral cancers account for 2-4% (Silverman 2001 and 2003). The
incidence rate ranges from 0.1-31.5/ 100,000 of population per annum, with the highest
rate reported from Melanesia and South Asia (Moore et al. 2000; Parkin et al. 2002). Oral
cancer in South and South East Asia accounts for 58% of total worldwide cases (Nair et al.
2004). Compared with other western countries, an unexpectedly high incidence of oral
cancer, exceeding 10/ 100,000 per year, has been reported from certain regions of France
(Moore et al. 2000; Parkin et al. 2002; Downer 2007). Oral cancer incidence and mortality
rates have increased in some parts of the world during the past decades, such as UK
(Conway et al. 2006), Brazil (Wünsch-Filho 2002), and Taiwan (Ho et al. 2002).
Lip cancer is the most common malignancy among oral cancers in some parts of the
western world, such as Australia (Moore et al. 1999 and 2001), Canada (Moore et al.
1999; Howell et al. 2003), Spain (Moore et al. 1999; Perea-Milla Lopez et al. 2003), and
Finland (Moore et al. 1999; Tarvainen et al. 2004). In Asia, the incidence rates, ranging
from 0 to 3%, are not as high as those reported for other oral cancers (Moore et al. 1999;
Parkin et al. 2002). In general, the incidence rate of lip SCC is higher in Caucasian men
(Lindqvist 1979a and b; Pukkala et al. 1994; Boyle 2001; Perea-Milla Lopez et al 2003;
Tarvainen et al. 2004).
For many countries, the tongue is reported to be the most dominant (20-40%) site of
presentation  of  oral  cancers  within  the  OC  (Gorsky  et  al.  2004).  In  India,  the  most
prevalent site is the buccal mucosa, where the betel (the main risk factor for oral cancers
in this area) is usually held (Warnakulasuriya and Ralhan 2007).
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2.2.2. Survival
Cancers  of  the  OC  have  high  mortality  rates,  and  despite  current  progress  in  cancer
treatment,  survival  rates  have  not  improved  dramatically  (Chen et  al.  1999;  Yeole  et  al.
2003; Bettendorf et al. 2004; Lam et al. 2006). The 5-year overall survival rates reported
for several parts of the world have ranged from 2, when distant metastases exist (Yeole et
al. 2003) to 95% (Shiboski et al. 2007) (Table 2.1.). Rates are extremely low for
developing countries, mainly due to the advanced stages of tumour at the time of
diagnosis. Local recurrence is the major cause of death (Woolgar et al. 1999).
Lip SCCs are less likely to cause mortality than are other cancers of the OC (Veness et al.
2001). The survival rate varies widely, depending on factors such as the stage of tumour at
the time of diagnosis, on recurrences, and on regional neck node metastases (Table 2.1.).
The highest survival rates, even up to 100%, have been reported for early stage tumours,
whereas the rates decrease to 50% or less when regional spread or neck metastasis occurs.
Most lip cancers are controlled successfully by complete surgical excision, but risk always
remains for developing recurrent tumours that require repeated surgical resections (Zitch
at al. 1995; de Visscher et al. 1999; McCombe et al. 2000; Babington et al. 2003).
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Table 2.1. Five-year survival rates for oral cancer patients, reported from different parts of
the world
Author/
year Location
Data
collection
period
N Inclusion criteria 5-year survival rate
Woolgar et
al. 1999 UK
1989-
1995 200
SCC1: Tongue, Buccal
mucosa, FOM2, Gum,
Retromular, Alveolus,
Oropharynx
Overall: 63%
By pathological TNM3 stage: I: 85%,
II: 90%, III: 82%, IV: 42%
Luukkaa et
al. 2003 Finland
1989-
1995 174
SCC: OC4, Oropharynx,
Hypopharynx
Overall: 32%, Cause-specific: 49%
By clinical TNM stage: I: 62%,
II: 63%, III: 57%, IV: 40%
By site: tongue: 65%, other OC:
45%, oropharynx: 64%
Rautava et
al. 2007 Finland
1988-
1997 188
SCC: Tongue, Gingiva,
FOM, hard palate, other OC
sites
Overall: 38%, disease-specific: 58%
Mork and
Glattre
1998
Norway 1953-1992 3640
Tongue, FOM, Other OC
sites, Oropharynx
Relative survival rate
by site: Tongue & FOM: 42%
Other OC sites: 44%, Oropharynx:
28%
Charabi et
al. 1997 Denmark
1978-
1982 156 OSCC
5
Overall: 37%
By clinical TNM stage: I: 61%,
II: 32%, III: 16%, IV: 17%
Charabi et
al. 2000 Denmark
1992-
1996 304 OSCC
3-year survival rate: Overall: 42%
By clinical TNM stage: I: 58%,
IV: 18%
Hemprich
& Muller
1989
Germany 1970-1985 352 SCC: Lip, OC, Oropharynx
Overall: 49%
By site: Lip: 69%, OC: 51%,
Oropharynx: 31%
By clinical TNM stage: I: 80%,
II: 63%, III: 43%, IV: 18%
Wutzl et
al. 2007 Austria
1990-
2000 222
SCC: OC, Oropharynx,
Stages II-IV Overall: 62%
Barzan et
al. 2002 Italy
1975-
1998 601
SCC, ICD6-9 141, 143-145,
149
Overall: 1975-1978: 23%,
1989-1993: 46%
Garzino-
Demo et
al. 2006
Italy 1989-2002 245
SCC: Tongue, Buccal
mucosa, FOM, Gingiva
Overall: 64%
By clinical TNM stage: I: 80%,
II: 78%, III: 48%, IV: 42%
Pericot et
al. 2000 Spain
1983-
1989 88 SCC: OC, Oropharynx
Overall: 79%
By clinical TNM stage: I: 82%,
II: 70%, III: 78%, IV: 48%
Antoniades
et al. 1995 Greece
1979-
1989 408 Lip SCC
Overall: 83.3%
By clinical TNM stage: I: 92%,
II: 68%, III: 40%, IV: 11%
Lung et al
2007 Romania
1993-
2002 352
Oral and maxillofacial
malignancies Overall: 31%
Hoffman
et al. 1998 US
1985-
1994 88035 Lip, OC, Oropharynx
By site: Lip: 91%, OC: 56%,
Oropharynx: 46%
Funk et al.
2002 US
1985-
1991 27598 ICD-O C02-C06 Overall: 51%, Overall SCC: 50%
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Shiboski et
al. 2007 US
1973-
2002 46855
Lip, Tongue, FOM, Gingiva,
Palate, Buccal mucosa
Relative survival: Lip: 68-95%,
Tongue: 25-59%, FOM: 32-67%,
Other OC: 68-95%
Bell et al.
2007 US
1993-
2003 215
SCC: Tongue, FOM,
Gingiva, Palate, Cheek,
Retromolar
Overall: 56%
Cerezo et
al. 1993 Canada
1976-
1985 117 Lip SCC Overall: 81%
Brandizzi
et al. 2005 Argentina
1950-
2000 1370 Oral cancer Overall: 39%
Carvalho
et al. 2004 Brazil
1953-
1997 3267
OC, Oropharyx, Lip
excluded
Overall: 29% (1950s), 43% (1990s)
By clinical TNM stage:
Decade 50: I & II: 53%, III & IV:
24%
Decade 90: I & II: 77%, III & IV:
32%
Lo et al.
2003 Taiwan
1975-
1996 378
SCC
ICD-9 140-145
Overall: 56%
By clinical TNM stage: I: 75%,
II: 66%, III: 49%, IV: 30%
Chen et al.
2004 Taiwan
1987-
1994 8114 ICD-9 140-149 Overall: 56%
Liu et al.
2006 Taiwan
1995-
2002 1010
Lip, Oral tongue, FOM,
Gingiva, Palate, Buccal
mucosa, Retromolar
Overall: 63%
Chen et al.
2007 Taiwan
1985-
1994 9039
ICD-9 140-141, 143-146,
148-149 Overall: 55%
Rao et al.
1998
India
(Bombay)
1987-
1989 1970 ICD-9 140-141, 143-145 Overall: 20-43%
Yeole et
al. 2003
India
(Bombay)
1992-
1994 1808 ICD-10 C00-C06
Overall: 40%, By clinical extent:
Localized: 59%, Regional: 16%,
Metastasis: 2%
Bilkay et
al. 2003 Turkey
1983-
1999 118 Carcinoma, Lower lip
Overall: 73% ,
By clinical TNM stage: I: 100%,
II: 94%, III: 67%, IV: 49%
Al-Rajhi et
al. 2002
Saudi
Arabia
1992-
1998 57
SCC, Stage IV
Tongue, Buccal mucosa,
FOM, Retromolar, Alveolus
Overall: 20%
Ma’aita
2000 Jordan
1989-
1998 118 Oral cancer
Overall: 53%, By clinical TNM
stage: I: 80%, IV: 20%
Inagi et al.
2002 Japan ---------- 221
SCC: Tongue, Buccal
mucosa, FOM, Gingiva,
Hard palate
By clinical TNM stage: I: 91%,
II: 73%, III: 63%, IV: 47%
Chandu et
al. 2005 Australia
1991-
2002 116
SCC: Lip, Tongue, Buccal
mucosa, Mandible, FOM,
Gum, Maxilla, Retromular,
Alveolus
Overall: 83%
By clinical TNM stage: I: 89%,
II: 84%, III: 83%, IV: 76%
1 Squamous cell carcinoma 2 Floor of the mouth 3 Tumour Node Metastasis 4 Oral cavity
5 Oral squamous cell carcinoma 6 International Classification of Diseases
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2.2.3. Aetiology and risk factors
Smoking and drinking are the main risk factors for head and neck cancers including oral
cancer. Tobacco smoking and alcohol consumption separately and independently cause
increased risk for oral cancer, and their combined use raises the risk expected with either
exposure alone (Blot et al. 1988; La Vecchia et al. 1997; Gillison 2007; Hashibe et al.
2007). Many investigators have concluded that at least 75-80% of oral cancers are
attributable to alcohol and tobacco exposure (Rodriguez et al. 2004; Gillison 2007;
Hashibe et al. 2007).
Strong dose-response relationships appeared for each substance after controlling for
exposure to the other (Blot et al. 1988; Hashibe et al. 2007). Oral cancer risk is related to
both intensity and duration of alcohol and tobacco consumption. In an effort to understand
the mechanisms of alcohol and tobacco interaction, what has been revealed is that the
combined risk for oral and pharyngeal cancers is multiplicative or at least greater than
additive (Blot et al. 1988; LaVecchia et al.1997).
The aetiology of lip cancer is partly distinct from that of OC cancer. Chronic exposure to
sunlight in the agricultural, forestry and fishing or any other out-door occupation, and
smoking, particularly pipe smoking, are the major risk factors (Lindqvist 1979a and b).
2.2.3.1. Tobacco
Tobacco contains at least 50 known carcinogens, including polycyclic aromatic
hydrocarbons such as tobacco-specific nitrosamines (TSNA) (Scully and Felix 2006;
Gillison 2007). Age at starting smoking has an inverse relation to oral cancer risk
(Llewellyn et al. 2004). Among ex-smokers, those who had quit smoking for more than
ten years showed odds ratios (ORs) near to one for the OC cancers (La Vecchia et
al.1997).
Smokeless tobacco products have several carcinogens; these carcinogens are, however,
fewer than those in smoking tobacco (Warnakulasuriya and Ralhan 2007). The high
incidence of oral cancer in South Asia, especially the Indian subcontinent, is attributed to
the use of smokeless tobacco products (Ahluwalia 2005).  There  are  mainly  two types  of
smokeless tobacco: chewing tobacco and snuff. Worldwide, several names are used for
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different smokeless tobacco products, such as gutkha, nass, toombak, shamma, and moist
snus (Warnakulasuriya and Ralhan 2007). Tobacco may also be added to areca nut or lime
(calcium hydroxide). The areca nut or the betel nut can be chewed alone or as a quid.
Although it  is  believed  that  the  added  tobacco  plays  the  primary  aetiological  role  in  the
development of oral cancer, areca products may play an independent role (Ahluwalia
2005).
Smokeless tobacco products differ greatly by region and culture. In the US, fermented
moist snuff and fire-cured dry snuff have high levels of TSNA, whereas air-cured chewing
tobacco is low in TSNA (Yen et al. 2007; Weitkunat et al. 2007). In Sweden, no
association has been found so far, between intensity or duration of moist snuff use which
is low in TSNA and oral cancer (Weitkunat et al. 2007).
2.2.3.2. Alcohol
Oral cancer risk significantly increases with both intensity and duration of alcohol
consumption, and it may increase directly with alcohol concentration (Huang et al. 2003;
Gillison 2007). Despite this, different studies suggest that all types of alcoholic beverages
contribute to oral cancer risk, with ethanol as the common ingredient being responsible
(Blot et al. 1988; La Vecchia et al. 1997; Altieri et al. 2004). Unexpectedly high incidence
of oral cancer in certain parts of France has been attributed to an excessive consumption of
crudely distilled spirit (Downer 2007). It has not yet been shown that alcohol itself is a
direct carcinogen; it may, however, interfere with carcinogenesis by different mechanisms.
Acetaldehyde the first metabolite of ethanol is a known carcinogen (Kurkivuori et al.
2007). Alcohol may also act as a solvent to increase mucosal exposure to carcinogens
(Blot et al. 1988, La Vecchia et al. 1997, Gillison 2007). Heavy alcohol consumption is
associated with nutritional deficiency, which may play a role in oral cancer incidence
(Blot et al. 1988).
2.2.3.3. Other risk factors
Oral cancer can occur in non-smokers and non-drinkers, so other factors may also play a
role in carcinogenesis. In the following lines some of these factors are discussed. Infection
with Human papilloma virus (HPV) is one of the risk determinants of oral cancers,
particularly those that involve the lingual and palatine tonsils within the oropharynx
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(Herrero et al. 2003; Hansson et al. 2005; Scully 2002; Scully 2005; Gillison 2007). The
estimated proportion of oral and oropharyngeal SCC attributable to HPV infection is 35%
(Hansson et al. 2005). The vast majority of HPV-DNA-positive patients harboured HPV-
16  (Hansson  et  al.  2005;  Herrero  et  al.  2003).  The  degree  to  which  oral  HPV  infection
may  contribute  to  increase  risk  for  oral  cancer  with  tobacco  or  alcohol  use  is  currently
unclear (Smith et al. 2004; Gillison 2007).
The relationship between diet and risk for oral cancer is well-established. It has been
clearly  shown  that  higher  intake  of  fresh  fruits  and  vegetables  (La  Vecchia  et  al.  1997;
Franceschi et al. 1999; Bosetti et al. 2003; Guneri et al. 2005; De Stefani et al. 2005;
Boeing et al. 2006; Pavia et al. 2006), and to some extent, olive oil (Franceschi et al. 1999,
Bosetti et al. 2003), is associated with lower risk for oral cancer, after controlling for the
effects of alcohol and tobacco. Various micro-nutrients, including vitamin C, beta-
carotene, and flavonoids are also inversely related to oral and pharyngeal cancer risk, but
generally less strongly than food groups (De Stefani et al. 2005; Gillison 2007). Total
calories, saturated oil, eggs, and starchy foods have emerged increasing oral cancer risk
(Franceschi et al. 1999, Bosetti et al. 2003).
It has been shown that poor oral health is associated with risk for oral cancer. Oral cancer
risk is inversely associated with some measures of oral hygiene, such as frequency of
tooth brushing and visits to a dental care provider (Moreno-Lopez et al. 2000; Guneri et al.
2005; Rosenquist et al. 2005). An independent role for oral hygiene was supported by
significant elevations in oral cancer risk among non-smokers and non-drinkers with poor
oral hygiene (Marshall et al. 1992).
2.2.4. Inheritance and genetic background
A positive family history such as having a sibling with oral cancer has been associated
with increased risk for oral cancer (Gillison 2007). Conditions carrying increased risk for
head and neck cancer include epithelial differentiation disorders, for instance dyskeratosis
congenital and DNA repair deficiency syndromes such as Blooms’ syndrome, Fanconi
anaemia, ataxia telangectasia, and xeroderma pigmentosum (Stewart and Kleihues 2003).
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Cancer can be defined as uncontrolled tissue growth in susceptible patients, which results
from an imbalance between cell division and programmed cell death (apoptosis). Oral
cancers arise as a consequence of complex multi-step interactions between genetic
susceptibility, behavioural factors such as tobacco use, and environmental factors such as
viruses (Winn et al. 1998; Scully et al. 2000; Kang and Park 2001). Some genetic effects
have been found in oral cancer patients but the exact process is not yet totally clear.
It  has  been  shown  that  loss  of  specific  chromosomal  regions  that  contain  tumour
suppressor genes is an early predictor of subsequent progression of oral potentially
malignant lesions to a cancer (Zhang and Rosin 2001). The p53 tumour suppressor gene
mutations are the genetic errors most frequently found in oral cancer, and the p53 gene is a
possible target for tobacco and alcohol (Jones 1998). Improved understanding of the
underlying genetic events of oral cancer suggests promising advances in early detection,
risk assessment, diagnosis, and prognostication, as well as novel approaches to treatment
(Scully et al. 2000; Bagan and Scully 2008).
2.3. Detection
2.3.1. Early detection of oral cancers
Poor survival of oral cancer patients is, at least in part, due to failure in the early detection
of small or potentially malignant lesions. Detection of oral cancer early is critical, because
patients with early-stage tumours have considerably better survival rates than patients with
advanced-stage tumours (Ship 2002). The treatment of oral cancer is expensive for the
society,  and  the  physical,  psychological,  and  emotional  impacts  have  considerable  costs
for the patients. Both morbidity and mortality associated with oral cancers can be reduced
by early detection. These cancers are known to be amenable to early detection, because
they mainly occur at sites that are visible and easily accessible to a painless, non-invasive
examination, making early detection relatively simple (Silverman 2001; Petersen 2005).
The WHO encourages all health care systems to focus on the prevention and early
detection of oral cancers as one of their main oral health targets. According to the Crete
Declaration on Oral Cancer Prevention in 2005 (TCDOCP 2005), access to health
facilities  and  provision  of  systems  for  early  detection  of  oral  cancers  needs  to  be
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strengthened worldwide, especially in countries with a high prevalence of oral cancers and
in the developing world.
2.3.2. Diagnostic delay
Although oral cancers arise in anatomically accessible areas, delayed diagnosis is common
(Stewart and Kleihues 2003). Diagnostic delay is usually defined as the time elapsed
between onset of symptoms and final diagnosis (McLeod et al. 2005). Delay in diagnosis
of oral cancers results in a reduction in survival and an increase in morbidity. The majority
of  patients  first  seek  professional  advice  only  when  a  tumour  is  already  well  advanced.
The 5-year survival for small and localized tumours approaches 80% or higher but falls to
10% or less for stage IV disease (Table 2.1).
2.3.2.1. Patient delay
The time period from the presentation of symptoms to diagnosis or the “diagnostic delay”,
is usually divided into two parts: “patient delay” and “professional delay” (McLeod et al.
2005). Patient delay is defined as the period between patient’s awareness of symptoms and
the  first  visit  to  a  professional.  In  many  reports  the  whole  diagnostic  delay  was  mostly
attributable to patient delay (Kowalski et al. 1994; Hollows et al. 2000; Kerdpon and
Sriplung 2001a and b; Onizawa et al. 2003; Brouha et al. 2005), which does not
necessarily mean that patients are solely responsible for it. Other factors such as access to
health care services and patients’ psychological factors must be taken into consideration
(Tromp et al. 2004 and 2005a; Diz Dios et al. 2005).
2.3.2.2. Professional delay
Professional delay is the time interval between a patient’s first consultation with a health
care professional and the definitive diagnosis and reflects the delay in patients’ being
referred to a specialist for confirmation by a histological diagnosis (McLeod et al. 2005).
Professional  delay  can  result  from:  failure  on  the  part  of  the  clinician  to  conduct  a
thorough examination, a low index of suspicion, and lack of experience with these
tumours (Diz Dios et al. 2005).
Some studies  show a  difference  between dentists  and  physicians  in  referring  oral  cancer
patients, indicating that professional delay is longer in patients referred by dentists (Scully
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et al. 1986; Kowalski et al. 1994). Paradoxically, other reports showed no significant
association between the health care professional degree and the delay (Wildt et al. 1995;
Kerdpon and Sriplung 2001b). However, several reports support the opinion that a dental
care provider is more likely to detect a lesion during a routine appointment than is a
medical provider (Gellrich et al. 2003; Lim et al. 2003; Holmes et al. 2003).
2.4. Prognosis
Advances in both surgical and non-surgical treatment of oral cancer have led to increased
local tumour control in recent years. However, overall survival and mortality rates have
not improved, due to advanced stage of tumour at the time of diagnosis, tumour
recurrences at regional sites, and occurrence of secondary primary tumours and distant
metastasis  (Braakhuis  et  al.  2002;  Marcus  et  al.  2004).  Patients  with  oral  SCC  (OSCC)
usually present with loco-regional disease, and the presence of distant metastasis at
diagnosis is not considered a common event. In spite of aggressive treatment, i.e., wide
tumour resection followed by radiotherapy and sometimes chemotherapy, tumour
recurrence may occur in 18–76% of oral cancer patients (Kowalski et al. 2005). Of the lip
cancer patients, 5–15% present with lymph node metastases, compared with more than
50–70% of those with tongue and FOM cancers (Stewart and Kleihues 2003).
2.4.1. Prognostic factors
Prognosis may be influenced by patient-related factors such as ethnicity (Scully and
Bedi 2000, Shiboski et al. 2007), socio-economic status (SES) (Chen et al. 2007) and
comorbidity (Ribeiro et al. 2000), tumour-related factors such  as  stage  (Marcus  et  al.
2004; Kowalski et al. 2005), histological grade (Keski-Säntti et al. 2007), and vascular or
peri-neural invasion (Bettendorf et al. 2004), and treatment-related factors (Kowalski et
al. 2005). Among these different factors there may exist interactions of various strengths.
2.4.1.1. Patient-related factors
Notable differences exist in oral cancer mortality between population groups according to
ethnicity  and  SES.  Evidence  shows,  for  men,  at  least,  that  people  with  lower  SES  have
worse survival than those from higher SES (Scully and Bedi 2000, Conway et al 2007;
Downer 2007).
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In the USA survival rates from oral cancer among blacks have been lower than among
whites (Scully and Bedi 2000; Morse and Kerr 2006; Shiboski et al. 2007), which has
been  due  to  lower  SES,  more  advanced  stage  of  disease,  and  differences  in  type  of
treatment they received (Scully and Bedi 2000). Difference in survival rate has also been
reported among three major ethnic groups in Taiwan, which has mainly been attributed to
the difference in their cultural, behavioural (betel quid-chewing habit) and socio-economic
differences (Chen et al. 2007). Incidence rate and mortality from oral cancer has also been
higher in American Hispanic men, from Puerto Rican origin (Cruz et al. 2006).
Some reports suggest that factors such as age, gender, and risk habits may have less or no
relevance to the prognosis of oral cancer once the patients are treated (Ribeiro et al. 2000;
Prieto et al. 2005). Comorbidity might be more important with regard to treatment
selection and prognosis (Ribeiro et al. 2000).
2.4.1.2. Tumour-related factors
Clinical and pathological Tumour, Node, Metastasis (TNM) stage is an important and
reliable predictor of survival (Chiesa et al. 1999). Details of TNM classification are in
Table 2.2.  Clinical  T  and  N  stage  and  the  presence  of  extra-capsular  spread  have  been
reported as the most important risk factors for the development of distant metastasis in
patients with oral SCC (Kowalski et al. 2005).
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        Table 2.2. TNM classification of oral cancers
TNM clinical classification (Sobin and Wittekind 2002)
T - Primary tumour
    TX   Primary tumour can not be assessed
    T0    No evidence of primary tumour
    Tis   Carcinoma in situ
    T1    Tumour 2 cm or less in greatest dimension
    T2    Tumour more than 2 cm but not more than 4 cm in greatest dimension
    T3    Tumour more than 4 cm in greatest dimension
    T4a   (Lip) tumour invades through cortical bone, inferior alveolar nerve, floor of the
             mouth, or skin (chin or nose)
    T4a   (Oral cavity) tumour invades through cortical bone, into deep/ extrinsic muscle of
             tongue, maxillary sinus, or skin of face
    T4b   (Lip and oral cavity) tumour invades masticator space, pterygoid plates or skull
             base, or encases internal carotid artery
* Superficial erosion alone of bone/ tooth socket by gingival primary is not sufficient to
   Classify a tumour as T4.
N - Regional lymph nodes
    NX   Regional lymph nodes cannot be assessed
    N0    No regional lymph node metastasis
    N1    Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension
    N2    Metastasis in a single ipsilateral lymph node, more than 3 cm but not more
             than  6 cm in greatest dimension; or in multiple ipsilateral lymph nodes,
             none more than 6 cm in greatest dimension; or bilateral or contralateral lymph
             nodes, none more than 6 cm in greatest dimension
    N2a  Metastasis in a single ipsilateral lymph node, more than 3 cm but not more
             than 6 cm in greatest dimension
    N2b  Metastasis in multiple ipsilateral lymph nodes, not more than 6 cm in
             greatest dimension
    N2c  Metastasis in bilateral or contralateral lymph nodes, not more than 6 cm
             in greatest dimension
    N3    Metastasis in a lymph node more than 6 cm in greatest dimension
* The regional lymph nodes are the cervical lymph nodes. Midline nodes are considered
   ipsilateral nodes.
M - Distant metastasis
    MX   Distant metastasis cannot be assessed
    M0    No distant metastasis
    M1    Distant metastasis
Stage                  TNM
   I                             T1N0M0
   II                            T2N0M0
   III                          T3N0M0
                                 T1,T2 or T3N1M0
   IV                          Any T4, N2, N3 or M1
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2.5. Treatment
2.5.1. Treatment modalities in oral cancer patients
The aim of treatment for oral cancer patients, as of any other cancer treatment, is to obtain
the highest cure rate and the lowest morbidity with minimal side effects. Surgery and
radiotherapy have been the mainstay of treatment for oral cancer. Surgery is the method of
choice for both tumour resection and tissue reconstruction (Boyle 2001). The decision
regarding treatment is influenced by several factors such as patient’s general health status
(Ribeiro et al. 2000), TNM stage of tumour at the time of diagnosis (Marcus et al. 2004;
Kowalski et al. 2005), tumour proximity to vital organs, clearance of surgical margins, and
presence of osseous, neural, or vascular invasion (Woolgar et al. 1999).
2.5.2. Preserving QOL in oral cancer patients
Cancers of the OC are highly fatal, and both the disease and the treatment have serious
morbid effects. All methods of treatment, surgery, radiotherapy, and chemotherapy, cause
significant side effects, especially as usually they are used in combination, simultaneously
or  consecutively.  Some  of  these  effects  are:  pain,  disfigurement  (Wax  et  al.  1999;
Knezevic et al. 2002), salivary dysfunction, mucositis, xerostomia (Parliament et al.
2004), swallowing disorders (Lazarus et al. 1996), osteoradionecrosis, and psychological
problems (Hassanein et al. 2001). Of these adverse effects some are of short duration, but
the others may persist for the patient’s lifetime. The QOL of oral cancer survivors
therefore, is generally poor (Ship 2002).
Management of oral cancer patients include a multiphase and continuous team approach.
The process needs collaboration among all specialists and health care workers involved in
the patient’s therapy (Boyle 2001). It also requires continuous and effective
communication among the patient and care providers (Hassanein et al. 2001). Patients
should be educated about the risk factors and encouraged not to continue smoking and
heavy drinking (Scully and Porter 2000). Therapy for salivary hypo-function or
dysfunction, prevention of new and recurrent dental caries, dental prostheses,
osseointegrated implants, and new surgical reconstructive techniques all help to preserve
and improve QOL (Ship 2002). Oro-dental care should also be performed before starting
any cancer therapy to prevent complications such as osteoradionecrosis (Scully and Felix
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2006). A more conservative bone resection can be considered as an option for preserving
the continuity of the mandible and its function when a non-infiltrative or erosive pattern of
mandibular invasion by a malignant oral tumour is evident (Brown et al. 2002).
2.6. Prevention
2.6.1. Primary prevention
The most important cause of preventable morbidity and mortality is tobacco use (Bsoul et
al. 2005). It is estimated to account for about 41% of oral/ pharyngeal cancer cases in men,
and  11% in  women (WHO 2005).  A recent  study  suggests  that  tobacco  cessation  at  the
earliest possible time in life is the most significant public health measure to control oral
cancer (Llwellyn et al. 2004).
Prevention  activities  focused  on  risk  factors  of  oral  cancer  can  be  through  existing  oral
health services or new community programmes targeted at different population groups
(Petersen 2003b). Oral health care professionals especially dentists, should further
investigate the patient’s family and social histories to elicit information about tobacco and
alcohol use (Bsoul et al. 2005).
2.6.2. Secondary prevention
Thorough inspection of OC in high-risk individuals facilitates early diagnosis of
potentially malignant lesions. However, the effectiveness of national organized screening
in reducing incidence of and mortality from oral cancer remains to be established (Stewart
and Kleihues 2003). Due to insufficient evidence on the costs, benefits, effectiveness,
feasibility, and appropriateness of screening for oral cancer, such a programme could not
be recommended (Daly et al. 2005). Thus, in the absence of science-based evidence for a
national screening programme, thorough and detailed examination of the OC and head and
neck region should be implemented during dental check-ups (Silverman 2001). This
examination composes the visual assessment and manual palpation of extra-oral head and
neck areas, intraoral soft tissues, and dental and periodontal tissues (Bsoul et al. 2005).
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3. AIMS OF THE STUDY
3.1. General aim
The  general  aim  of  the  present  study  was  to  investigate  the  burden  of  oral  cancers  in
Tehran, Iran.
3.2. Specific objectives
To achieve this aim, the following specific objectives were set:
1. To determine the patient and tumour characteristics of oral cancers in Tehran, Iran
2. To evaluate survival rates in patients with OC cancer
3. To evaluate survival rates in patients with lip cancer
4. To evaluate the delay in diagnosis of OC cancer
3.3. Hypotheses
Working hypotheses: a) Most oral cancer patients in Tehran, Iran, have advanced tumours
at the time of diagnosis. b) Survival rates between oral cancer patients in early and late
tumour stages significantly differ. c) The difference between survival rates in these
patients is due to the delay in diagnosis.
30
31
4. MATERIALS AND METHODS
4.1. Study background
According to the 2003 report of the IMOHME, based on the data from 70% of the
country’s pathology centres and hospitals, oropharyngeal cancers accounted for 3% of all
cancers in Iran. There existed no population based cancer registry in Iran during the study
period, which made it impossible for us to provide a reliable incidence or prevalence rate.
To the researcher’s knowledge, no research reports are available regarding oral cancers in
Tehran, Iran.
4.2. Study population
The target population of this study comprised three groups: 1) a retrospective cohort of
oral cancer patients attending 30 hospitals in Tehran, Iran during 1993-2003 (n=1042), 2)
a retrospective cohort of OC (n=470) and lip (n=82) cancer patients attending five
university hospitals in Tehran, Iran, during 1996-2003, and 3) consecutive OC cancer
patients attending three main university hospitals in Tehran during September 2004 to
September 2006 (n=100).
4.3. Pilot study
A  pilot  study  was  performed  in  two  stages,  to  revise  the  contents  of  the  data  collection
form and the study questionnaire and to test the feasibility of the study method. In order to
revise the contents of the primary data collection form, a study was conducted by
reviewing 50 head and neck cancer patients’ records in three hospitals. Another study was
performed in the second stage with ten head and neck cancer patients other than OC
cancer patients, such as those with cancer of the larynx to revise the primary
questionnaire.
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4.4. Data collection
Patient and tumour characteristics: For determining the characteristics of malignant
oral tumours, data were obtained from patient records of 1042 patients diagnosed with
invasive oral cancers during 1993-2003 in 30 major hospitals in Tehran. Primary tumour
sites were recorded according to the 10th revision of the International Classification of
Disease coding system (WHO 2003) using ICD codes from C00 to C10. This
classification is shown in Table 4.1. In this study, oral cancers on the lip, tongue, gum,
FOM, other sites in the mouth (including buccal mucosa, labial mucosa, palatal mucosa,
retro-molar area, and unspecified areas), tonsil, oropharynx and major salivary glands
were included. Data were analysed in three groups according to tumour aetio-pathological
similarities: tumours of the lips (C00), of the OC (C01-C06; C09-C10), and of major
salivary glands (C07-C08).
Survival rate: To evaluate the survival rates in oral cancer patients the study included a
retrospective cohort of 470 primary OC and 82 lip cancer patients diagnosed at five
university hospitals in Tehran in 1996-2003.
Diagnostic delay: To assess delay in diagnosis, 100 patients with primary OC SCC (ICD-
10 sites C01-C06) (WHO 2003), consecutively referred to three university hospitals in
Tehran during September 2004 to September 2006, were studied.
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Table 4.1. Primary tumours’ anatomical sites 1
  Malignant neoplasms of lip (C00)
1. External upper lip (vermilion border)
2. External lower lip (vermilion border)
3. Commissures
4. Mucosa of upper and lower lips (buccal or oral aspects of lips)
Malignant neoplasms of oral cavity and oropharynx (C01-C06, C09-C10)
1. Tongue (C01-C02)
      a. Base of tongue posterior to the vallate papilla (posterior third)
            b. Dorsal surface and lateral borders anterior to vallate papilla (anterior two-
                thirds)
            c. Anterior ventral surface, fraenulum linguae
            d. Lingual tonsil
2. Upper alveolus and gingiva (upper gum) (C03)
3. Lower alveolus and gingiva (lower gum) (C03)
4. Floor of the mouth (C04)
5. Hard and soft palate, uvula (C05)
6. Buccal mucosa (C06)
a. cheek mucosa
b. retro molar areas
c. upper and lower buccal/ labial sulci (vestibule of the mouth)
d. minor salivary glands
7. Tonsil, tonsillar fossa, tonsillar pillars (C09)
8. Valleecula, anterior surface of epiglottis, oropharynx (C10)
  Malignant neoplasms of major salivary glands (C07-C08)
1. Parotid gland (C07)
2. Submandibular gland, Sublingual gland (C08)
1 Modified from International Classification of Diseases (ICD), ICD-10 (WHO 2003)
4.5. Theoretical model of the study
The theoretical concept of the study is shown in Figure 4.1. According to this model,
incidence, survival (mortality) rate, health-related QOL, and financial burden are the four
main components of the total burden of oral cancer. By putting the patient and tumour
characteristics and tumour detection in associations with the disease burden, this model
assumes that it is possible to modify the burden by changing the related factors. This
would be the basis for primary (targeting risk behaviours) and secondary prevention (early
detection and reduction of diagnostic delay) of oral cancers. The present study’s focus was
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on  the  epidemiologic  part  of  the  oral  cancer  burden,  i.e.,  patient  and  tumour
characteristics, survival rate, and diagnostic delay.
Fig. 4.1. Theoretical model of the study
4.6. Questions and variables
4.6.1. Patient characteristics
The data collection form included sections for personal data such as patient’s age at time
of diagnosis, gender, and place of residence.
4.6.2. Tumour characteristics
Tumour characteristics included in the data collection form were histo-pathological type,
primary tumour anatomical site, and tumour stage at diagnosis. TNM staging of tumours
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was according to clinical staging (Sobin and Wittekind 2002) based on T (tumour size, at
the largest diameter) N (nodal involvement), and M (metastasis) status as recorded in the
patient files.
4.6.3. Survival
For survival analysis, the patients were followed from the date of diagnosis to late 2005.
We defined survival as the time from diagnosis until December 31, 2005 or until death due
to oral cancer, whichever occurred first. Vital status was ascertained through a
combination of information from patient records, telephone calls, and the death-register
files at the IMOHME. Information abstracted from patient records included birth year,
gender, date of diagnosis; TNM stage, primary tumour site, and histopathology type.
Treatment  modality  (surgery,  pre-  or  postoperative  radiotherapy,  chemotherapy)  and  the
final admittance dates to the hospital were also recorded, as were the date and the cancer
or non-cancer causes of death.
4.6.4. Diagnostic delay
Data were obtained by means of structured questionnaire-interviews that inquired about
patient demographics such as gender, age, marital status, and place of residence, smoking
history, dental visits, the initial source of referral to the centre, date of onset of symptoms,
and date of consulting the first professional. The medical record of each patient was
reviewed  to  retrieve  information  on  date  of  diagnosis,  primary  tumour  site,  and  TNM
stage  of  tumour  at  diagnosis.  Diagnostic  delay  was  defined  as  the  period  from  onset  of
symptoms to the final diagnosis of oral cancer (McLeod et al. 2005). This period was
divided into two phases: 1) time from onset of symptoms to patient’s first professional
visit (patient delay) and 2) time from the first professional visit to the final diagnosis
(professional delay). Interviews were performed before the beginning of any cancer
therapy.
4.7. Statistical methods
Chi-square, t-test, and ANOVA served to test for needed statistical significance between
subgroups for mean values and frequencies. Regression models were applied to determine
the extent to which the factors were able to explain variation in the data. The terms of the
models facilitated the calculation of the corresponding ORs and their 95% confidence
intervals (CI). Survival curves were generated by Kaplan-Maier methods. The
relationships between survival status and other study factors were evaluated by the log-
rank test. For further survival analysis Cox’s regression model was adopted to calculate
the hazard ratios.
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5. RESULTS
5.1. What are the patient and tumour characteristics of oral cancers in
Iran (I)?
Oral cancers were studied separately in three groups: OC, lip, and salivary glands. OC
tumours were more frequent (65%). The majority of all cancer patients were men (59%)
and in the 41-64 age group (43%). The mean age of the patients was 61.2 (SD 15, median
64, range 14-103), 58.7 (SD 14, median 62, range 27-87), and 51.5 (SD 17, median 52,
range 6-85) for OC, lip, and salivary gland cancers, respectively (P <  0.001).  A  clear
gender and age difference emerged between patients with these tumours (P < 0.001).
Males dominated, especially in lip cancers (85%), and the majority of the patients in all
these three groups were over 40 (Table 5.1). Further analyses showed no gender
difference by age within these three tumour sites (Figure 5.1). Tongue cancers were the
most  prevalent  OC type  (50%).  No age  and  gender  difference  appeared  among OC sub-
sites (Table 5.2).
Table 5.1. Primary tumour site in oral cancer patients (n = 1042) by gender and age
Tumour site
Oral cavity Lip Salivary glandsVariable No (%)
No (%) No (%) No (%)
P-value
Sex
Female 426 (41) 319 (47) 22 (15) 85 (38)
Male 616 (59) 356 (53) 124 (85) 136 (62)
0.00
Age (years)
? 40 152 (15) 76 (11) 19 (13) 57 (26)
 41-64 449 (43) 277 (41) 69 (47) 103 (47) 0.00
65 or more 441 (42) 322 (48) 58 (40) 61 (27)
Total 1042 (100) 675 (100) 146 (100) 221 (100)
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Fig. 5.1. Distribution (%) of oral cancer patients (n = 1042) by age, men and women
separately, for three tumour sites (no gender difference by age within sites)
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Table 5.2. Primary tumour site in oral cavity cancer patients (n = 675) by gender and age
Oral cavity
Tongue
(C01-C02)
Gingiva
(C03)
Floor of the
mouth
(C04)
Buccal
mucosa
(C05-C06)
Oropharynx
(C09-C10)
Variable No (%)
No (%) No (%) No (%) No (%) No (%)
P-value
Gender
Female 319 (47) 175 (52) 26 (43) 21 (44)  87 (41) 10 (53)
Male 356 (53) 161 (48) 35 (57) 27 (56) 124 (59) 9 (47)
0.12
Age (years)
? 40  76 (11)   31 (9)  7 (12)  3 (6) 31 (14) 4 (21)
41-64 277 (41) 142 (42) 22 (36) 18 (38) 88 (42) 7 (37)
65 or more 322 (48) 163 (49) 32 (52) 27 (56) 92 (44) 8 (42)
0.35
Total 675 (100) 336 (100) 61 (100) 48 (100) 211 (100) 19 (100)
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Most  of  the  OC  cancer  patients  (59%)  were  in  advanced  stages  (stages  III  or  IV)  at
diagnosis, whereas 29% of lip cancers were diagnosed in late stages (Table 5.3). Data
regarding TNM staging were missing from patient records in 15% of cases.
Regarding the histological type of tumours 87% of OC cancers were SCC; this figure was
95% for lip cancers. Salivary gland tumours were mostly mucoepidermoid carcinomas
(28%). For all the three sites the occurrence of SCCs increased at successively older ages.
Of all histological types, SCCs comprised 48%, 72%, and 81% in patients aged 40 and
younger, 41 to 64, and those aged 65 and older, (P < 0.001).
Table 5.3. Stage of tumours at diagnosis in oral cancer patients (n = 882) by gender, age,
and primary tumour site.
Stage of tumours
I or II III or IVVariable No (%)
No (%) No (%)
P-value
Sex
Female 370 (42) 172 (43) 198 (41)
Male 512 (58) 224 (57) 288 (59)
0.23
Age (years)
? 40 125 (14)  51 (13)  74 (15)
41-64 382 (43) 175 (44) 207 (43) 0.60
65 or more 375 (43) 170 (43) 205 (42)
Tumour site
Oral cavity 578 (66) 237 (60) 341 (70)
Lip 121 (14) 86 (22) 35 (7) 0.00
Salivary gland 183 (20) 73 (18) 110 (23)
Total 882 (100) 396 (100) 486 (100)
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5.2. How long is the survival of oral cancer patients in Iran after
diagnosis (II, III)?
Oral cavity cancer patients’ survival:
The overall 5-year survival of the OC cancer patients was 30%. For the survival analysis,
these patients were followed for a maximum of 116 months (mean (SD) 32 (26), range 0-
116). Of all 470 patients, 335 (71%) died of their oral cancer, 18 patients (4%) died of
other causes, 80 (17%) survived, and 37 (8%) were lost to follow-up. No associations
emerged between gender and age and patient survival. However, stage of tumour at
diagnosis and treatment were related to survival. Patients diagnosed at stages III or IV had
shorter survival than those diagnosed at stages I or II (P < 0.05) (Figure 5.2). The outlook
was  also  poor  for  patients  treated  with  radiotherapy  alone;  they  were  more  likely  to  die
sooner (P < 0.05). No difference existed in patient survival according to histological type
of tumour (Table 5.4).
Fig. 5.3. Survival rate in oral cavity cancer patients (n = 470) by stage of tumour at
diagnosis
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Further analysis by Cox’s multivariate method showed that stage of tumour at the time of
diagnosis and treatment were the most important determinants of survival compared with
age, gender, and histological type of OC tumour (Table 5.4). Overall survival was longer
for patients with cancer in stages I or II than for those with stages III or IV (OR = 3, 95%
CI = 2.2-4.2). Longer survival was evident for patients treated with surgery than for those
who had undergone surgery together with radiotherapy, or radiotherapy alone (OR = 2.8,
95% CI = 1.7-4.5).
Table 5.4. Five-year survival rates for OC (n = 470) and lip cancer (n = 82) patients by
age, gender, stage of tumour at diagnosis, treatment, and histological type.
Five-year Survival rates (%) a
No (%) P-value bVariable
Oral cavity Lip
Oral cavity Lip
Oral cavity Lip
Sex
Female 213 (45) 12 (15) (25) *
Male 257 (55) 70 (85) (31) (65)
0.68 0.32
Age (years)
? 40 57 (12) 13 (16) (33) (36)
41-64 193 (41) 35 (43) (32) (66)
65 or more 220 (47) 34 (41) (25) (65)
0.33 0.35
Stage of tumour
I 92 (20) 35 (43) (51) (81)
II 73 (16) 17 (21) (44) (75)
III 70 (15) 11 (13) (13) (45)
IV 167 (35)   9 (11) (12) *
Missing 68 (14) 10 (12)
0.00 0.00
Treatment
Surgery 70 (15) 34 (42) (54) (69)
Surgery +
radiotherapy
274 (58) 35 (43) (27) (75)
Radiotherapy 72 (15)   6 (7) (08) *
Missing 54 (12)   7 (8)
0.00 0.00
Histology
SCC c 404 (86) 77 (94) (29) (62)
Non-SCC   66 (14) 5 (6) (33) *
0.47 0.62
Total 470 (100) 82 (100) (30) (62)
 a Kaplan-Maier analysis   b log-rank test c Scuamous cell carcinoma * not estimated due to small n.
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Lip cancer patients’ survival:
The overall five-year survival rate of the lip cancer patients was 62%. Gender, age, and
histological  type  were  not  associated  with  survival.  Treatment  modality  and  stage  of
tumour at diagnosis were related to survival (Table 5.4.). Patients treated with surgery
were more likely to have a longer survival (P < 0.05). Patients diagnosed at stages III or
IV had a dismal prognosis and lower survival rates (P < 0.05) (Figure 5.3).
Fig. 5.3. Survival rate in lip cancer patients (n = 82) by stage of tumour at diagnosis
The multivariate analysis using Cox’s regression method showed that treatment modality
and stage of tumour were the most important determinants of lip cancer patients’ survival
(Table 5.5.). The overall survival was longer for patients diagnosed at early stages than in
those  diagnosed  at  stages  III  or  IV  (OR  =  3,  95%  CI  =  1.1-7.9).  Patients  treated  with
radiotherapy alone had lower survival rates than did those who had undergone the other
treatment methods (OR = 7.7, 95% CI = 1.3-39.7).
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Table 5.5. Determinants of length of survival assessed by Cox’s regression analysis in
patients with cancer of the OC (n = 470) and lip (n = 82).
ES 1 SE 2 OR 3 95% CI 4 P-value
Variable
OC 5 Lip OC Lip OC Lip OC Lip OC Lip
Sex
(Male a, female) 0.2 0.5 0.1 0.6 1.2 1.6 0.9-1.6 0.5-5.2 0.11 0.40
Age group (years)
? 40 a 1
41-64 0.4 1.1 0.2 0.8 1.5 3.0 0.9-2.3 0.7-13.9 0.08 0.15
65 or more 0.4 0.7 0.2 0.7 1.5 2.0 1.0-2.3 0.5-7.9 0.07 0.33
Stage
(I or II a, III or IV) 1.1 1.0 0.1 0.5 3.0 3.0 2.2-4.2 1.1-7.9 0.00 0.02
Treatment
Surgery a 1
Surgery +
radiotherapy
0.7 0.1 0.2 0.5 1.1 1.1 0.7-1.6  0.4-3.1 0.73 0.91
Radiotherapy 1.0 2.0 0.2 0.8 2.8 7.7 1.7-4.5  1.3-39.7 0.00 0.01
Histology
 (SCC 6, a, non-SCC) 0.1 1.0 0.2 0.9 1.1 2.9 0.7-1.5  0.5-16.1 0.73 0.23
1 Estimate of strength 2 Standard error 3 Odds ratio 4 Confidence interval 5 Oral cavity
6 Squamous cell carcinoma a reference category
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5.3. How much time elapses between symptoms’ notice by patients and
diagnosis of oral cancers in Iran (IV)?
The time elapsed between oral  cancer patients’ first  notice of the symptoms and definite
diagnosis, i.e., the diagnostic delay, ranged from 1 to 36 months, with a mean of 7.2
months  (SD  7.5,  median  4).  The  mean  patient  and  professional  delays  were  5.3  months
(SD 6.1, median 2) and 2.1 months (SD 2.1, median 1), respectively. Mean delays by age,
gender, marital status, place of residence, tumour site, stage of tumour, smoking history,
referral source, and dental visit are shown in Figure 5.2.
Marital status, stage of tumour at diagnosis and occurrence of dental visit within the past
12 months were associated with diagnostic delay (P < 0.05). Patients living without a
spouse, those diagnosed with an advanced-stage tumour, and patients with no dental visits
within the past 12 months were more likely to have longer diagnostic delays. Logistic
regression analyses revealed that the most important determinants of a diagnostic delay of
more than four months were being single (OR = 4.8; 95% CI 1.5-14.8; P < 0.05) and being
at advanced stages of disease at the time of diagnosis (OR = 5.2; 95% CI 1.8-15.6;
P<0.01).
Patients with advanced tumour stages were more likely to have longer patient delay than
those at early stages (OR = 5.6; 95% CI 1.8–17.3; P < 0.05), as were patients living alone
(OR = 7.1; 95% CI 2.0–24.7; P < 0.05). Logistic regression analysis revealed that
advanced stage of tumour at diagnosis (OR = 3.4; 95% CI 1.2–9.4; P < 0.05) and living
alone (OR = 3.5; 95% CI 1.2–10.3; P < 0.05) were determinants of professional delays of
more than one month.
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Fig. 5.2. Mean  patient,  professional,  and  diagnostic  delay  in  oral  cavity  cancer  patients
(n=100), by different factors
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6. DISCUSSION
6.1. Methodological considerations
The present study investigated patient and tumour characteristics of oral cancers in
Tehran, Iran, during a ten-year period from 1993 to 2003, with the main focus on OC
cancers. The study further evaluated survival rates and the time elapsed between
symptoms being noticed by oral cancer patients and the diagnosis. A nation-wide
population-based cancer registry in Iran began in 2003; therefore we used hospital-based
data in order to have a general preview of oral cancers in Tehran.
Of the more than 100 hospitals in Tehran, 30 hospitals are involved in oral cancer
treatment. All the university, military, and main private hospitals, in addition to the Cancer
Institute of Iran, provided data for the study. The Cancer Institute of Iran was established
in 1955 by the National Red Cross Foundation as the first comprehensive cancer centre in
Iran, providing diverse programmes in prevention, early detection, patient care, education,
community activities, and international collaboration.
Although the patients studied came from 30 major hospitals in Tehran, the lack of a
nation-wide population-based cancer registry until 2003 makes it difficult to give exact
prevalence or incidence values for oral cancers. Therefore for the period 1993 to 2003, we
evaluated the patient and tumour characteristics for oral cancers.
All eligible patients were identified from the patient attendance list and information files
held in the records department of each hospital. No patient can be admitted to a hospital or
treated without first filling in the required forms and documents. Study data collection
forms and records files were cross-checked to ensure inclusion of all eligible cases.
For the survival analysis of oral cancer patients, vital status was ascertained through a
combination of information from patient records, telephone calls, and death register files
at the Iran Ministry of Health. To evaluate the time elapsed from patient noticing of
symptoms  and  the  diagnosis  of  oral  cancer,  all  the  information  gathered  during  the
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interviews and all the patients’ responses were validated by referring to and checking them
with their medical records at the hospital, or at the physician’s or dentist’s office.
6.2. Results of the study
6.2.1. Patient and tumour characteristics
Oral cancer has traditionally been a disease dominated by the male gender (Moore et al.
2000; Silverman 2001; Stewart and Kleihues 2003). Higher alcohol and tobacco use and
outdoor occupations in men have been considered the main reasons for the male
predominance, whereas recent reports from different parts of the world show a decreasing
male to female ratio among OC cancer patients (Luukkaa et al. 2003; Tarvainen et al.
2004; Rautava et al. 2007). This has been attributable to an increase in smoking among
women, particularly in western countries. In the present study, oral cancer occurred more
frequently in men, with a male to female ratio of 1.4:1. Smoking prevalence is estimated
as 20 to 26% among Iranian males and 2 to 4% among females (Mosavi-Jarahi et al.
2004). This may be a plausible reason for the higher occurrence of oral cancers in Iranian
men.
Similar to the vast  majority of the previous reports from all  over the world (Moore et  al
2000; Parkin et al. 2002, Silverman 2003) only a small proportion of OC tumours were in
patients aged 40 and younger, average age at the time of diagnosis was 61, and SCC was
the  most  frequent  histological  type  of  OC  and  lip  cancers.  Among  all  OC  cancers,  the
tongue was the most common site of occurrence, in accordance with that reported from
different parts of the world, mostly western counties such as the UK (Moore et al. 2000).
Oral SCC is amenable to early detection and clearly attributable to lifestyles, smoking, and
alcohol drinking, so it is usually regarded as preventable. Although SCC is the most
prevalent  type  of  malignant  oral  tumours,  each  distinct  histological  type  needs  to  be
considered according to the individual prognosis in patient management and treatment.
Almost 60% of the OC cancer patients were at stage III or IV at diagnosis. Late diagnosis
of oral cancers generally results in a very poor prognosis and strongly reduced survival
rates. Oral cancer treatment in advanced stages means radical surgical resection and
comprises complicated post-operative reconstructive procedures. Furthermore, surgery
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should be accompanied by radiotherapy and sometimes chemotherapy. The present results
speak for the necessity of a national programme underscoring early detection of oral
cancer.
6.2.2. Survival
Oral cavity cancer:
The overall survival outcome for oral cancer is dismal, with the 5-year survival being
around 50%. The 5-year survival in the present study is comparable with that reported
from developing countries. Further analysis showed that OC cancer patients with stage I or
II tumours had the longest survival, while the lowest was in later stages. This reveals the
smaller influence of treatment when tumours have been diagnosed in advanced stages.
Patients treated with radiotherapy alone had shorter survival than those who were treated
surgically or who had been operated on and had had adjuvant radiotherapy. Of all patients
who had radiotherapy as the sole treatment modality, 71% were at an advanced disease
stage at the time of diagnosis and were plausibly in poor general health. These findings
support earlier reports regarding the relation between treatment and survival in patients
with OC cancer (Chen et al. 1999; Carvalho et al. 2004; Chen et al. 2004).
Primary surgical management with adjuvant radiotherapy has been associated with high
rates of local control in previous reports (Chen et al. 1999; Woolgar et al. 1999; Davidson
et al. 2001; Carvalho et al. 2004). However, the reason for longer survival found here for
patients treated by operation alone may be mainly that this method is used for treatment of
earlier tumours.
The  decision  to  treat  is  based  not  only  on  the  stage  of  tumour  but  also  on  several  other
factors  such  as  the  general  health  of  the  patient,  state  of  surgical  margins,  and  in  some
instance by the patient’s decision about treatment. These all may have an impact on the
outcome of the treatment and on survival.
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Lip cancer:
Lip cancer is a form of oral cancer but has a distinct epidemiology and different tumour
behaviour (Moore et al. 1999). Although this cancer is not common in Asia, in contrast to
other oral cancers which are prevalent in southern parts of this continent, more thorough
assessments are needed, since lip cancer is usually considered to be easily detectable and
thus curable (Zitsch et al. 1995; de Visscher et al. 1999).
In the present study, lip cancer patients’ overall survival rates for 1, 2, and 5 years after
diagnosis were 91%, 86%, and 62%. These figures are lower than those reported from
western countries. One possible reason may be delay in treatment which leads to the much
higher percentage of advanced SCCs at the time of treatment and thus lower survival of lip
cancer patients.
It was found that malignant lip tumours occurred mostly in men, on the lower lip, and as
SCCs. The findings revealed that gender, age, and histological type of tumours were
insignificant predictors of survival, both in univariate and multivariable analyses. The
results regarding the relationship of lip cancer patients’ survival with gender, age, tumour
stage, treatment modality, and histo-pathological type were in line with previous results
(Moore et al. 1999; de Visscher et al. 1999; Boyle 2001; Babington et al. 2003). Survival
was higher in patients diagnosed at earlier tumour stages. Many previous reports also
show higher survival rates for patients diagnosed at stages I or II (de Visscher et al. 1999;
McCombe et al. 2000; Babington et al. 2003; Vartanian et al. 2004).
In the present study, further analyses showed that patients treated with radiotherapy alone
had lower survival rates than those who had undergone surgery together with or without
adjuvant radiotherapy. These findings support previous studies which show higher rates of
recurrence and lower disease-free survival in lip cancer patients initially treated with
radiotherapy (de Visscher et al. 1999, Zitsch et al. 1999).
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6.2.3. Delay in diagnosis
Early diagnosis of oral cancers leads to higher survival rates and better quality of life
outcomes (Kowalski et al. 1994; Onizawa et al. 2003). In the present study the mean
patient, professional, and diagnostic delays were higher than those reported from other,
especially developed, countries (Dimitroulis et al. 1992; Jovanovic et al. 1992; Rubright et
al. 1996; Kerdpon and Sriplung 2001a; Pitiphat et al. 2002). No national programme exists
for the prevention of oral cancers in Iran which may explain these findings.
This study mainly shows that the “patient delay” constitutes a substantial part of the total
delay time elapsed between the onset of symptoms and diagnosis. Such finding is in
agreement with those reported by other investigators (Kowalski and Carvalho 2001;
Hollows et al 2000; Kerdpon and Sriplung 2001a and b; Onizawa et al. 2003; Brouha et al.
2005). As the majority of oral cancer patients in the present study had advanced-stage
tumours at diagnosis, patient delay in seeking medical attention may be a contributing
cause in a considerable number of OC cancer patients’ deaths.
Although the time period from patients’ first awareness of symptoms to the first
professional visit is called the “patient delay”, patient is not the only one responsible.
Other factors such as access to health care services contribute to the length of this time
(Diz Dios et al. 2005). Oral cancer patients may have insufficient or incorrect knowledge
to appropriately interpret the relevance of their symptoms to a malignancy, and they may
consider the symptoms to be non-serious or harmless (De Nooijer et al. 2001; Scott et al.
2006) or possibly fail to seek help due to fear of cancer or lack of faith in medical
treatment (De  Nooijer  et  al.  2001).  Psychological  factors  such  as  distress  and  coping
styles, as well as socio-economic factors have been shown to affect patients’ health-
seeking behaviours (Tromp et al. 2004; Tromp et al. 2005a; Scott et al. 2006).
The present findings reveal that patients living alone had greater tendencies for longer
patient and, surprisingly, professional delays. Married patients may have better health
habits and mutual support and indeed seek medical care with less delay (Scott et al. 2005),
which may be mainly due to the supportive and motivational role of their partners (Tromp
et al. 2004). Another plausible explanation for this finding is the lack of comprehensive
and socially supportive health care for cancer patients in Iran.
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Previous studies have reported different results regarding the association between an
advanced stage of disease at the time of diagnosis and delay in diagnosis (Carvalho et al.
2002; Pitiphat et al. 2002; Onizawa et al. 2003; Ho et al. 2004; McGurk et al. 2005;
McLeod et al. 2005; Scott et al. 2005). In the present study, as in some others (Kerdpon
and Sriplung 2001a and b; Pitiphat et al. 2002; Onizawa et al. 2003), an advanced stage of
tumour was associated with a longer diagnostic delay as well as with its two components:
patient and professional delay.
Three major hypotheses may explain the controversies regarding the association between
tumor stage and diagnostic delay: 1) the “tumor biology” or “tumor aggressiveness”
hypothesis: patients with slow-growing tumors may experience longer diagnostic delay,
however, they are more likely to be diagnosed with an early stage tumor than patients with
fast-growing tumors, 2) the “misdiagnosis” or “silent tumor” hypothesis: patients with
silent oral tumors may notice the minor changes early and consult a doctor (short patient
delay), but the professional misdiagnoses the lesion as benign (long professional delay)
which  leads  to  an  advanced  stage  tumor  at  the  time  of  diagnosis  (Carvalho  et  al.  2002;
Scott et al. 2005), and 3) “logical” hypothesis. Our findings favor the “logical” hypothesis,
which suggests that a longer diagnostic delay (both patient and professional) is related to
an advanced tumor stage at the time of diagnosis (Carvalho et al. 2002).
Findings of the present study show that not having visited a dentist within the past 12
months was a significant determinant of patient delay. Patients who do not regularly visit a
dentist seemed more likely to neglect their cancer-related symptoms or to misinterpret
them as common oro-dental problems. One recent study (Bayat et al. 2006) revealed that
52% of Iranian adults aged 18 years or more had visited a dentist within the past 12
months, whereas only 16% of our patients reported having a dental visit within this period.
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7. CONCLUSIONS
The specific conclusions of the study are:
1. Among all 1042 oral cancer patients’ records studied, OC tumours were most
frequent. The majority of all cancer patients were men and in the 41-64 age group.
Most OC cancer patients were at advanced stages at the time of diagnosis.
2. The overall five-year survival rate of patients with OC cancer was 30%. Survival
was negatively related to stage of tumour at the time of diagnosis.
3. The  overall  five-year  survival  rate  of  patients  with  lip  cancer  was  62%.  The
survival  was  higher  in  patients  diagnosed  at  earlier  tumour  stages  than  in  those
diagnosed at advanced stages.
4. The mean diagnostic delay found in this study was 7.2 months (SD 7.5), and
“patient delay” constitutes a substantial part of the total time elapsed between the
onset of symptoms and diagnosis.
8. RECOMMENDATIONS
The current study provides, for the first time, data as a baseline for interventions regarding
the prevention of oral cancer in Iran. Considering possible future trends in the important
risk factors such as smoking and chronic sun exposure in Iranian society, the data reported
here are fundamentally important for use as a baseline for comparing any changes in oral
cancer burden in terms of patient and tumour characteristics, survival rates, and diagnostic
delay. This will help health care providers to organize an oral cancer prevention
programme in Iran.
Based on the findings of this study, developing preventive programmes that focus on
raising public awareness of the signs and symptoms of oral cancer is essential to
promoting earlier diagnosis and treatment in Iran. In addition to people’s need for
knowledge about oral cancer, they should be encouraged to be more conscious of any
changes in the mouth which may develop into a malignancy.
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Health care professionals, especially dentists and oral hygienists, should also be
empowered to ensure that many potentially malignant and malignant lesions are
recognized early and accurately. There is a clear need, in this regard, for additional
training and for greater vigilance by the health work-force. Ongoing continuing education
(CE) programmes for health care professionals, comprising theoretical and hands-on
courses regarding oral cancer prevention and early detection, are greatly needed. The
present study also speaks for more emphasis on oral cancer prevention and early detection
in undergraduate medical and dental education.
Topics of CE courses cover various dental and medical subjects, so oral cancer prevention
and early detection can be easily emphasized in CE courses using the existing structure of
education for health care professionals in Iran. Oral cancer prevention should also be
highlighted  in  congresses  and  seminars  to  present  and  discuss  the  latest  concepts.  If
successful, these programmes could lead to faster diagnosis and better treatment outcomes
for oral cancer patients.
In order to reduce the burden of oral  cancer on the community recommended policies at
the national administrative level are empowering the newly established nationwide
population-based cancer registry, conducting interventions at community level to increase
public awareness of the importance of early detection of oral cancers, removal of barriers
to health-care system utilization by oral cancer patients, and mandating training
programmes for health care professionals and encouraging comprehensive oral
examination and patient-tailored risk counselling especially by dentists. An oral cancer
prevention programme can be added to other cancer prevention programmes, especially
cancers that share the common risk factors, such as pulmonary and oesophageal cancers.
Further population-based studies on oral cancers and advances in their risk assessment, in
surveillance and prevention, as well as evaluating patient-related QOL, and the financial
burden of disease will be crucial for controlling the substantial threat of these cancers to
public health.
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9. SUMMARY
Although of low frequency in most countries, oral cancer is highly fatal, especially in
advanced tumour stages. Despite many advances in treatment and rehabilitation
techniques, there has been no improvement in the survival of oral cancer patients for
decades, worldwide. This alarming indicator of disease burden highlights the importance
of implementing preventive strategies focusing on early detection of malignant lesions,
which requires the active contribution of the medical and dental work force. Because of
their intimate knowledge of the oral cavity (OC), dentists are uniquely positioned to
examine their patients for indications of developing oral cancer, and to counsel them about
the oral health consequences of tobacco and alcohol use as the leading risk factors for oral
cancer.
The present study, which was done for the first time, assessed the burden of oral cancer in
Tehran, Iran, in terms of patient and tumour characteristics, survival and delay in
diagnosis. The working hypothesis was that most oral cancer patients in Iran have
advanced tumours at the time of diagnosis and that survival rates between oral cancer
patients in early and late tumour stages significantly differ, which may be due to the delay
in diagnosis.
Major referral hospitals (n=30) in Tehran, were selected, and patient records of 1042
patients diagnosed with invasive oral cancers during 1993-2003 were reviewed. Data were
analysed in three groups according to primary tumour site: tumours of the lips, OC, and
major salivary glands. For survival analysis, 470 patients with OC and 82 patients with lip
cancers were followed from the date of diagnosis to late 2005. To assess the time elapsed
between the presentation of symptoms and the final diagnosis, i.e., diagnostic delay, 100
patients with primary OC squamous cell carcinoma (SCC), consecutively referred to three
university hospitals in Tehran during September 2004 to September 2006, were separately
studied.
A data collection form and a questionnaire were designed and piloted to inquire about
patient demographics, smoking history, dental visits, the initial source of referral to the
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centre, date of onset of symptoms, and date of consulting the first professional. The
medical record of each patient was reviewed to retrieve information on the date of
diagnosis, primary tumour site, and TNM stage of tumour at the time of diagnosis. TNM
staging was according to clinical staging based on T (tumour size, at the largest diameter)
N (nodal involvement), and M (metastasis) status as recorded in the patient files.
Questionnaire-interviews were performed for the 100 consecutive patients before the
beginning  of  any  cancer  therapy.  Diagnostic  delay  was  divided  into  two phases:  1)  time
from onset of symptoms to patient’s first professional visit (patient delay) and 2) time
from first professional visit to final diagnosis (professional delay).
The results showed that the majority of the OC cancer patients were at advanced tumour
stages at the time of diagnosis. The overall five-year survival rate was 30% and 62% for
OC  and  lip  cancer  patients,  which  is  low  particularly  as  compared  to  the  rates  reported
from developed countries. Patients who were at stages III or IV at diagnosis had the lowest
survival rate. The mean “diagnostic delay”, i.e., time elapsed from patient’s first noticing
symptoms and the definite diagnosis, was longer (mean 7.2 months, SD 7.5), than that
reported from many other countries and the “patient delay” constituted the substantial part
of the total diagnostic delay.
In general it can be concluded that based on the present results, public awareness about the
signs and symptoms of oral cancer should be increased. An improvement in the preventive
orientation of all health care providers, especially dentists, is also required, which can
come through emphasizing routine and thorough examination of the OC and head and
neck region and early detection of potentially malignant and malignant lesions. Providing
dentists, oral hygienists, and medical doctors with the opportunity to attend continuing
education courses, seminars, and congresses on prevention of oral cancer will be helpful in
this regard. Oral cancer prevention and early detection, as well as related public and health
care provider education, are significant public health concerns that require increased and
sustained attention in both the health care and policy systems.
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12. APPENDIX
                             Data collection form and questionnaire1
Oral cancer in Tehran Iran: an approach for understanding the disease
burden
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1 Combined version of the data collection form and questionnaire for oral cancer
patients
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1. Personal characteristics:
  1.1. Sex: male--- female---
  1.2. Year of birth: -----------
  1.3. Place of residence: Urban--- Rural---
  1.4. Marital status: Single--- married---
  1.5. Family name: ----------------------- name: --------------------
  1.6. Father’s name: -------------------------
  1.7. Residential full address: ---------------------------------------------------------------------
  1.8. Phone number: --------------------------
[Items 1.5. to 1.8. were retrieved for patients studied for their survival status.]
2. Tobacco Smoking:
    2.1. History of smoking: Never been a smoker--- Former smoker--- Smoker---
    2.2. If former smoker: have not smoked for --- years
    2.3. If smoker, the duration: --- years
3. Dental service utilization:
    3.1. When was your last dental visit?
           Within 6 months--- 6 months to 1 year ago---1-2 years ago--- 2 to 5 years ago---
            more than 5 years ago--- never--- don't remember---
    3.1. What was the reason for your last dental visit?
            I had trouble with my teeth or gums--- for regular check up--- others (specify the
            reason) ------------------------------------ I don't remember---
4. Tumour characteristics:
  4.1. Primary tumour site: C00--- (C01-C02)--- C03--- C04--- (C05-C06)--- (C07-C08)--
         (C09-C10)---
  4.2. Histopathology type: SCC--- ACC--- Sarcoma--- Not specified--- Others (specify)
         ---------------------------
  4.3. T (Tumour size): TX--- T1--- T2--- T3--- T4--- Not specified---
  4.4. N (Nodal involvement): NX--- N0--- N1--- N2--- N3--- Not specified---
  4.5. M (Metastasis): MX--- M0--- M1---
  4.6. Overall tumour stage: I--- II--- III--- IV--- I or II--- III or IV--- Not specified---
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5. Initial symptoms:
Pain--- swelling without pain--- ulceration--- white lesion--- Other (specify)---------------
  none--- don't know---
6. Initial dental or medical professional visited by the patient:
  Dentist--- Physician--- Oral and maxillofacial surgeon--- Others (specify) --------
  don't remember------
7. Time between first noticing symptoms to final diagnosis:
  7.1. The date of first noticing symptoms: ---/---/ --- (dd/mm/yy) don't remember---
         not noticing any symptoms---
  7.2. The date of first professional visit: ---/---/ --- (dd/mm/yy) don't remember---
  7.3. The date of diagnosis: ---/---/ --- (dd/mm/yy) don't remember---
8. History of Treatment for the malignancy:
  8.1. Surgery: No--- Yes---
  8.2. Radiotherapy: No--- Yes--- if yes, preoperative--- postoperative---
  8.3. Chemotherapy: No--- Yes---
  8.4. Recurrent tumour history: No--- Yes--- not mentioned----
8.5 Previous treatment for malignancies? No----Yes--- if yes what? -----------------
          don't remember---
  8.6. Final admittance date to the hospital: ---/---/ --- (dd/mm/yy) don't remember---
9. Survival status:
  9.1. Alive --- dead--- lost to follow-up ---
  9.2. Date of death: ---/ ---/ --- (dd/mm/yy)
  9.3. Cause of death: ------------------------
